Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin versus sitagliptin versus no metformin after TIA or minor ischemic stroke with impaired glucose tolerance
NL-OMON25556Phase 2Active, not recruiting
- Sponsor
- Erasmus MC
- Start
- Jan 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of metformin and sitagliptin in prediabetes (3 arms), sponsored by Erasmus MC. Primary endpoint: Baseline-adjusted difference in 2-hour post-load glucose at 6 months. Started Jan 2014; status: active, not recruiting.
02
Drugs
metforminsitagliptin
03
Conditions
prediabetes
Beyond the preview
Go deeper on NL-OMON25556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON25556.